mutLBSgeneDB |
Gene summary for ATF2 |
Gene summary |
Basic gene Info. | Gene symbol | ATF2 |
Gene name | activating transcription factor 2 | |
Synonyms | CRE-BP1|CREB-2|CREB2|HB16|TREB7 | |
Cytomap | UCSC genome browser: 2q32 | |
Type of gene | protein-coding | |
RefGenes | NM_001256090.1, NM_001256091.1,NM_001256092.1,NM_001256093.1,NM_001256094.1, NM_001880.3,NR_045768.1,NR_045769.1,NR_045770.1, NR_045771.1,NR_045772.1,NR_045773.1,NR_045774.1, | |
Description | activating transcription factor 2 splice variant ATF2-var2cAMP response element-binding protein CRE-BP1cAMP responsive element binding protein 2, formerlycAMP-dependent transcription factor ATF-2cAMP-responsive element-binding protein 2cyclic AMP-dep | |
Modification date | 20141222 | |
dbXrefs | MIM : 123811 | |
HGNC : HGNC | ||
Ensembl : ENSG00000115966 | ||
HPRD : 00443 | ||
Vega : OTTHUMG00000132424 | ||
Protein | UniProt: P15336 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ATF2 | |
BioGPS: 1386 | ||
Pathway | NCI Pathway Interaction Database: ATF2 | |
KEGG: ATF2 | ||
REACTOME: ATF2 | ||
Pathway Commons: ATF2 | ||
Context | iHOP: ATF2 | |
ligand binding site mutation search in PubMed: ATF2 | ||
UCL Cancer Institute: ATF2 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0006970 | response to osmotic stress | 21098032 | GO:0006974 | cellular response to DNA damage stimulus | 22304920 | GO:0016573 | histone acetylation | 10821277 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 16300731 |
Top |
Ligand binding site mutations for ATF2 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | R363 | R363K | SKCM | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for ATF2 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R363 | R363K | -0.62101543 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for ATF2 from PDB |
Top |
Differential gene expression and gene-gene network for ATF2 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for ATF2 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0027651 | Neoplasms | 2 | AlteredExpression, Biomarker |
umls:C0242656 | Disease Progression | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for ATF2 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of ATF2 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of ATF2 |
Multiple alignments for P15336 in multiple species |
LBS | AA sequence | # species | Species | K372 | SRCRQKRKVWV | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | N362 | KFLERNRAAAS | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R355 | DPDEKRRKFLE | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R361 | RKFLERNRAAA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R363 | FLERNRAAASR | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R370 | AASRCRQKRKV | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |